Advances in Tumor Targeting Biomimetic Drug Delivery Systems: A Promising Approach for Antitumor Therapy DOI Creative Commons

Ziyi Mo,

Jiao He,

Man Li

et al.

Pharmaceutical Fronts, Journal Year: 2024, Volume and Issue: 06(02), P. e101 - e118

Published: May 22, 2024

Abstract Cancer is one of the most fatal diseases that attract numerous efforts and attention from researchers. Among plentiful therapeutic agents, chemotherapy frequently used in treating virulent tumors, its insistent administration useful ablation cancers; however, it also produces side effects. Biomimetic drug delivery systems (BDDSs) provide an alternative route for antitumor therapy. Their endogenous substances may be extracellular vesicles, living cells, cell membranes, etc., which optimize single-agent chemotherapy. They “upgrade” traditional platforms by combining original with itself, disguised as a Trojan Horse, to trick immune system or tumor tissues achieve higher targeting lower immunogenicity. Herein, we review three BDDS strategies being recently development their advances, aiming at providing general guidelines opportunities this field future.

Language: Английский

Cancer cell membrane-coated nanoparticles: a promising anti-tumor bionic platform DOI Creative Commons

Qiuyan Guo,

Shengmei Wang,

Rubing Xu

et al.

RSC Advances, Journal Year: 2024, Volume and Issue: 14(15), P. 10608 - 10637

Published: Jan. 1, 2024

This review summarized the function of cancer cell membranes and comprehensively discussed preparation membrane-coated nanoparticles (CCM-NPs) their application in anti-tumor therapy. The graphical abstract figure was drawn by Figdraw (https://www.figdraw.com).

Language: Английский

Citations

19
Cell membrane-camouflaged bufalin targets NOD2 and overcomes multidrug resistance in pancreatic cancer DOI Creative Commons
Wei Zhang,

Yibao Fan,

Jinze Zhang

et al.

Drug Resistance Updates, Journal Year: 2023, Volume and Issue: 71, P. 101005 - 101005

Published: Aug. 21, 2023

Multidrug resistance in pancreatic cancer poses a significant challenge clinical treatment. Bufalin (BA), compound found secretions from the glands of toads, may help overcome this problem. However, severe cardiotoxicity thus far has hindered its application. Hence, present study aimed to develop cell membrane-camouflaged and BA-loaded polylactic-co-glycolic acid nanoparticle (CBAP) assess potential counter chemoresistance cancer.The toxicity CBAP was evaluated by electrocardiogram, body weight, distress score, nesting behavior mice. In addition, anticarcinoma activity underlying mechanism were investigated both vitro vivo.CBAP significantly mitigated BA-mediated acute enhanced sensitivity several drugs, such as gemcitabine, 5-fluorouracil, FOLFIRINOX. Mechanistically, directly bound nucleotide-binding oligomerization domain containing protein 2 (NOD2) inhibited expression nuclear factor kappa-light-chain-enhancer activated B cells. This inhibits ATP-binding cassette transporters, which are responsible for cells.Our findings indicate that NOD2. Combining with standard-of-care chemotherapeutics represents safe efficient strategy treatment cancer.

Language: Английский

Citations

30
Biomembrane‐coated nanosystems as next‐generation delivery systems for the treatment of gastrointestinal cancers DOI Creative Commons
Joana Lopes, Daniela Lopes, Mahzad Motallebi

et al.

Bioengineering & Translational Medicine, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 26, 2025

Abstract Gastrointestinal cancers, a major global cause of cancer‐related mortality and disease burden, are heterogeneous group malignant aliments involving different organs the digestive system. The late clinical diagnosis, genomic tumor heterogeneity, high complexity gastrointestinal microenvironment, along with increasing treatment resistance have been recognized as main contributing factors to current inadequacy interventions poor prognosis cancer patients. In coming years, is unfortunately predicted increase due absence early detection effective therapeutic options. Biomembrane‐coated biomimetic nanoparticles (NPs) recently appointed advanced nanotechnological tools for management cancers. These comprise not only cell‐mimicking nanodevices (the pioneers this top‐down coating technology), but also exosome bacterial mimetics. Due their enhanced bio‐interfacing features, biocompatibility, immune evasion, specific targetability tumorous tissues, these nanostructures successfully exploited provide safer, effective, targeted applications. This review highlights latest research on biomembrane‐coated nanosystems therapy diagnosis most common deadliest subtypes namely colorectal cancer, gastric liver esophageal pancreatic cancer. challenges toward translation mentioned.

Language: Английский

Citations

1
Brain gliomas: Diagnostic and therapeutic issues and the prospects of drug-targeted nano-delivery technology DOI Creative Commons

Baoqin Song,

Xiu Wang,

Lijing Qin

et al.

Pharmacological Research, Journal Year: 2024, Volume and Issue: 206, P. 107308 - 107308

Published: July 15, 2024

Glioma is the most common intracranial malignant tumor, with severe difficulty in treatment and a low patient survival rate. Due to heterogeneity invasiveness of tumors, lack personalized clinical design, physiological barriers, it often difficult accurately distinguish gliomas, which dramatically affects subsequent diagnosis, imaging treatment, prognosis. Fortunately, nano-delivery systems have demonstrated unprecedented capabilities diagnosing treating gliomas recent years. They been modified surface efficiently traverse BBB/BBTB, target lesion sites, intelligently release therapeutic or contrast agents, thereby achieving precise treatment. In this review, we focus on systems. Firstly, provide an overview standard emerging diagnostic technologies for glioma practice. After induction analysis, summarizing delivery methods drug systems, design nanoparticles, their new advances Finally, discussed prospects potential challenges drug-delivery glioma.

Language: Английский

Citations

8
Insights into lenvatinib resistance: mechanisms, potential biomarkers, and strategies to enhance sensitivity DOI
Qiang You, Rong Li,

Jia Yao

et al.

Medical Oncology, Journal Year: 2024, Volume and Issue: 41(3)

Published: Feb. 21, 2024

Language: Английский

Citations

7
Emerging platelet-based drug delivery systems DOI Open Access

Mengkun Fang,

Rui Liu, Yile Fang

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 177, P. 117131 - 117131

Published: July 15, 2024

Drug delivery systems are becoming increasingly utilized; however, a major challenge in this field is the insufficient target of tissues or cells. Although efforts with engineered nanoparticles have shown some success, issues targeting, toxicity and immunogenicity persist. Conversely, living cells can be used as drug-delivery vehicles because they typically innate targeting mechanisms minimal adverse effects. As active participants hemostasis, inflammation, tumors, platelets great potential drug delivery. This review highlights platelet-based systems, including platelet membrane engineering, coating, cytoplasmic loading, genetic synthetic/artificial for different applications.

Language: Английский

Citations

7
A structured biomimetic nanoparticle as inflammatory factor sponge and autophagy-regulatory agent against intervertebral disc degeneration and discogenic pain DOI Creative Commons
Kanglu Li, Wenbo Yang,

Xuanzuo Chen

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Aug. 14, 2024

Abstract Lower back pain (LBP) is a common condition closely associated with intervertebral disc degeneration (IDD), causing significant socioeconomic burden. Inflammatory activation in degenerated discs involves pro-inflammatory cytokines, dysregulated regulatory and increased levels of nerve growth factor (NGF), leading to further destruction sensitization. Macrophage polarization related autophagy. Based on these pathological features, structured biomimetic nanoparticle coated TrkA-overexpressing macrophage membranes (TMNP@SR) rapamycin-loaded mesoporous silica core developed. TMNP@SR acted like sponges adsorbe inflammatory cytokines NGF delivers the autophagy regulator rapamycin (RAPA) into macrophages through homologous targeting effects outer engineered cell membrane. By regulating activation, promoted M1-to-M2 switch avoid continuous inflammation within disc, which prevented apoptosis nucleus pulposus cells. In addition, relieved mechanical thermal hyperalgesia, reduced calcitonin gene-related peptide (CGRP) substance P (SP) expression dorsal root ganglion, downregulated GFAP c-FOS signaling spinal cord rat IDD model. summary, spontaneously inhibits aggravation alleviate reduce ingress sensory nerves, presenting promising treatment strategy for LBP induced by degeneration. Graphical

Language: Английский

Citations

6
Biomembrane-Modified Biomimetic Nanodrug Delivery Systems: Frontier Platforms for Cardiovascular Disease Treatment DOI Creative Commons

Yunan Gu,

Lixin Du,

Yuxin Wu

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(8), P. 960 - 960

Published: Aug. 7, 2024

Cardiovascular diseases (CVDs) are one of the leading causes death worldwide. Despite significant advances in current drug therapies, issues such as poor targeting and severe side effects persist. In recent years, nanomedicine has been extensively applied research treatment CVDs. Among these, biomembrane-modified biomimetic nanodrug delivery systems (BNDSs) have emerged a focus due to their unique biocompatibility efficient capabilities. By modifying with biological membranes, BNDSs can effectively reduce recognition clearance by immune system, enhance circulation time vivo, improve targeting. This review first provides an overview classification pathological mechanisms CVDs, then systematically summarizes progress discussing design principles, functional characteristics, clinical application potential. Finally, it highlights challenges faced translation BNDSs.

Language: Английский

Citations

5
Nanomaterials: leading immunogenic cell death-based cancer therapies DOI Creative Commons

Changyu Ma,

Zhe Cheng, Haotian Tan

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: Aug. 9, 2024

The field of oncology has transformed in recent years, with treatments shifting from traditional surgical resection and radiation therapy to more diverse customized approaches, one which is immunotherapy. ICD (immunogenic cell death) belongs a class regulatory death modalities that reactivate the immune response by facilitating interaction between apoptotic cells releasing specific signaling molecules, DAMPs (damage-associated molecular patterns). inducers can elevate expression proteins optimize TME (tumor microenvironment). use nanotechnology shown its unique potential. Nanomaterials, due their tunability, targeting, biocompatibility, have become powerful tools for drug delivery, immunomodulators, etc., significant efficacy clinical trials. In particular, these nanomaterials effectively activate ICD, trigger potent anti-tumor response, maintain long-term tumor suppression. Different types nanomaterials, such as biological membrane-modified nanoparticles, self-assembled nanostructures, metallic mesoporous materials, hydrogels, play respective roles induction structures mechanisms action. Therefore, this review will explore latest advances application common discuss how they provide new strategies cancer therapy. By gaining deeper understanding mechanism action researchers develop precise effective therapeutic approaches improve prognosis quality life patients. Moreover, hold promise overcome resistance conventional therapies, minimize side effects, lead personalized treatment regimens, ultimately benefiting treatment.

Language: Английский

Citations

5
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives DOI Creative Commons
Yuhang Chen,

Shengyuan Dai,

Chien‐shan Cheng

et al.

Journal of Hematology & Oncology, Journal Year: 2024, Volume and Issue: 17(1)

Published: Dec. 21, 2024

Lenvatinib is a multi-target tyrosine kinase inhibitor widely used in the treatment of hepatocellular carcinoma (HCC). Its primary mechanism action involves inhibiting signal pathways such as vascular endothelial growth factor receptors (VEGFR) and fibroblast (FGFR), thereby reducing tumor cell proliferation angiogenesis affecting tumor's immune microenvironment. In liver cancer, although lenvatinib monotherapy has shown good clinical effect, problem drug resistance becoming more serious. This may be caused by variety factors, including genetic mutations, signaling pathway remodeling, changes order to overcome resistance, combination other therapeutic strategies gradually become research hotspot, it worth noting that checkpoint inhibitors (ICIs) application prospect. not only enhances anti-tumor response but also helps improve efficacy. However, therapy faces challenges regarding safety tolerability. Therefore, studying mechanisms identifying relevant biomarkers particularly important, aids early diagnosis personalized treatment. article reviews treating efficacy its with inhibitors, causes exploration biomarkers, novel for lenvatinib. We hope provide insights into use scientific settings, offering new cancer.

Language: Английский

Citations

5